Atlas Trials

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

Clinical trial NCT06964230 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06964230
Sponsor
T3D Therapeutics, Inc.
Status
NOT_YET_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Alzheimer's Disease
Start date
2026-10-26
Primary completion
2031-04-01
Enrollment
376

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.